(Q36662912)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

review article

1 reference

title

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Daryl D DePestel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Peggy L Carver

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

language of work or name

English

0 references

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

1730-1744

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Systemic mycoses in the immunocompromised host: an update in antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Overview: pathogenesis of fungal infections in the organ transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Fungal infection in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Overview: fungal infections in the transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Treatment of opportunistic mycoses: how long is long enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Systemic antifungal agents. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Drug interactions of the newer oral antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Pharmacokinetic drug interactions with antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Does differing metabolism by cytochrome p450 have clinical importance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Induction of fluconazole metabolism by rifampin: in vivo study in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

P-glycoprotein and drug therapy in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from In Vitro Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Mechanisms of clinically relevant drug interactions associated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

History of the development of azole derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Role of itraconazole metabolites in CYP3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Drug-drug interactions of antifungal agents and implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

21 January 2018

Intravenous itraconazole

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Clinical pharmacokinetics of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Update on drug interactions with azole antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Coadministration of itraconazole and tacrolimus after thoracic organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Sirolimus and ketoconazole co-prescription in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Fluconazole-sirolimus drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Demographic considerations in tacrolimus pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

The clinical and economic potential of cyclosporin drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

Blood concentrations of everolimus are markedly increased by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1730

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.12.1730

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17125435%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference